权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Molecular mechanisms of gefitinib-induced rash formation: Gefitinib augments lipogenesis and steroidgenesis in sebaceous glands

吉非替尼诱导皮疹形成的分子机制：吉非替尼增强皮脂腺的脂肪生成和类固醇生成

基本信息

批准号：
22590506
负责人：
SATO Takashi
金额：
$ 2.75万
依托单位：
Tokyo University of Pharmacy and Life Science
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2010
资助国家：
日本
起止时间：
2010 至 2012
项目状态：
已结题

项目摘要

A small-molecule tyrosine kinase inhibitor, gefitinib, which targets the ligand-binding domain of epidermal growth factor receptors, exhibits anti-tumorigenic activity in patients with advanced non-small cell lung cancer. Many patients treated with gefitinib develop an acne-like rash on the face and upper body. Although acne is characterized as a functional disorder in sebaceous glands and pilosebaceous units, there have been no reports to date that gefitinib may modulate sebum production in sebaceous glands. In the present study, a mass spectrometry analysis revealed that orally administrated gefitinib was detectable in a pustule from a patient treated with gefitinib but not ones from four acne patients. In addition, gefitinib augmented the production of triacylglycerols (TG), the major sebum component, and perilipin, a sebocytic differentiation marker, in human and hamster sebocytes. Furthermore, gefitinib facilitated steroidogenesis in both hamster and human sebocytes. Therefore, these results provide novel evidence that gefitinib exists in the hair follicle of the skin after its oral administration and directly facilitates sebum production by the augmentation of TG production. Moreover, the augmentation of sebum production is likely to due to the increases of androgen synthesisin sebocytes. These findings will help to increase the clinical understanding of the side effects of gefitinib, and improve the QOL of patients being treated with gefitinib

吉非替尼是一种小分子酪氨酸激酶抑制剂，靶向表皮生长因子受体的配体结合域，在晚期非小细胞肺癌患者中表现出抗肿瘤活性。许多接受吉非替尼治疗的患者在面部和上身出现痤疮样皮疹。虽然痤疮的特征是皮脂腺和毛囊皮脂腺单位的功能障碍，但迄今为止还没有报道吉非替尼可以调节皮脂腺中的皮脂产生。在本研究中，质谱分析显示，口服吉非替尼可检测到的脓疱从吉非替尼治疗的患者，但不是从四个痤疮患者。此外，吉非替尼增加了人和仓鼠皮脂细胞中主要皮脂成分三酰甘油（TG）和皮脂细胞分化标志物周脂蛋白的产生。此外，吉非替尼促进仓鼠和人皮脂腺细胞中的类固醇生成。因此，这些结果提供了新的证据，证明吉非替尼在口服给药后存在于皮肤的毛囊中，并通过增加TG的产生直接促进皮脂的产生。此外，皮脂生成的增加可能是由于皮脂细胞中雄激素合成的增加。这些发现将有助于提高临床对吉非替尼副作用的认识，改善吉非替尼治疗患者的生活质量